(1) Department of Biomedical and Biotechnological Sciences, University of Catania,
(2) Department of Medical and Surgery Sciences, University of Catania,
(3) School of Human and Scocial Science, “Kore” University of EnnaEnna, Italy;
(4) Centro Scienze dell’Invecchiamento e Medicina Traslazionale-CeSI-Met Chieti, Italy
* Correspondence: maiolino@policlinico.unict.it y These authors contributed equally to this work.
Received: 9 December 2019; Accepted: 27 December 2019; Published: 31 December 2019
In the December 2019, the International Journal of Molecular Sciences reported findings from a clinical trial in 40 MD patients suffering from cochlear sensorineural hearing loss. The research, by the University of Catania, has yielded promising results in the study of MD.(5)
The university researchers found that 22 MD patients supplemented with a nutritional mushroom biomass preparation of Coriolus versicolor (3 g/day for 2 months) experienced significant improvement in severity of tinnitus(†) and mood scores(*) compared with 18 MD patients who did not receive the mushroom biomass preparation.
Additionally, biomarkers of oxidative stress(‡) and defence response(§), were improved in MD patients treated with Coriolus versicolor, but were unchanged in the untreated group. This suggests that:
• systemic oxidative stress exists in patients affected by MD
• supplementation with Coriolus versicolor enhances the body’s defence mechanisms against oxidative damage.
(*) Significant improvement in scores for anger, confusion, depression, fatigue and tension (vigour was unchanged), based on questionnaire.
(†) Significant improvement in tinnitus handicap inventory (frequency range, average hearing loss in decibels and verbal discrimination), based on questionnaire.
(‡) Increased plasma protein carbonyls, hydroxynonenals and ultraweak luminescence and F2-isoprostanes.
(§) Increased lymphocyte levels of vitagenes (genes that encode heat shock proteins) such as heme oxygenase-1, heat shock protein 72, thioredoxin, sirtuin-1 and ɣ-GC liase; and an increase in the plasma ratio of reduced glutathione vs oxidised glutathione.
The Coriolus versicolor used in this preclinical study was supplied by Mycology Research Laboratories Ltd.
Link to the study
https://www.ncbi.nlm.nih.gov/pubmed/31906226
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Full Article
Clinical articles
-
Impact of Gastrointestinal Tract on Mushroom Biomass: Deciphering Their Potential on Gut Microbiota Modulation.
Helena Araújo-Rodrigues, Ana Sofia Salsinha, João Bettencourt Relvas, Freni K. Tavaria, Manuela E. Pintado Presented at the the 10th International Human Microbiome Consortium (IHMC) Congress held on June 22-25, 2024 in Rome Italy. -
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential.
Rosanna Di Paola, Rosalba Siracusa, Roberta Fusco, Marialaura Ontario, Gaetano Cammilleri, Licia Pantano, Maria Scuto, Mario Tomasello, Sestina Spanò, Angela Trovato Salinaro, Ali S. Abdelhameed, Vincenzo Ferrantelli, Antonio Arcidiacono, Tilman Fritsch, Gabriella Lupo, Anna Signorile, Luigi Maiolino, Salvatore Cuzzocrea, and Vittorio Calabrese.
Curr Neuropharmacol 2023 Dec 8. PMID: 38073105
-
Mushrooms as Functional Foods for Ménière’s Disease.
Victoria Bell and Tito Horácio Fernandes.
Appl. Sci. 2023, 13, 12348. -
Antioxidants, Hormetic Nutrition, and Autism.
Modafferi Sergio, Lupo Gabriella, Tomasello Mario, Rampulla Francesco, Ontario Marialaura,
Scuto Maria, Trovato Salinaro Angela, Arcidiacono Antonio, Anfuso Carmelina Daniela,
Legmouz Maria, Azzaoui Fatima-Zahra, Palmeri Agostino, Spano’ Sestina, Biamonte Francesca,
Cammilleri Gaetano, Fritsch Tilman, Sidenkova Alena, Calabrese Edward, Wenzel Uwe and Calabrese Vittorio. Curr Neuropharmacol. 2023 Aug 17.